TY - JOUR T1 - Early Effects of Transplatin on Oncogene Activation <em>In Vivo</em> JF - Anticancer Research JO - Anticancer Res SP - 3997 LP - 4002 VL - 24 IS - 6 AU - A. NÉMETH AU - E. NADASI AU - A BERO AU - L. OLASZ AU - A. EMBER AU - A. KVARDA AU - L. BUJDOSO AU - I. ARANY AU - A. CSEJTEI AU - ZS. FALUHELYI AU - I. EMBER Y1 - 2004/11/01 UR - http://ar.iiarjournals.org/content/24/6/3997.abstract N2 - The aim of the study was to investigate the early effect of Transplatin (the stereo-isomer of Cisplatin) on oncogenes in inbred CBA/Ca mice. Cisplatin is commonly used for the treatment of squamous cell carcinomas of the head and neck. Cisplatin has a strong oncogene activation effect compared to the structural analogue Transplatin. Body weight equivalent amounts of a human dose of Transplatin were administered intraperitoneally to 6- to 8-week-old, inbred, female CBA/Ca mice. Twenty-four, 48 and 72 hours after the treatment, RNA was isolated from the target organs and the expressions of c-myc, Haras and p53 genes were examined. Investigation of early changes showed no significant overexpression compared to Cisplatin, which had a significant effect on oncogene expression in the “short-term” in vivo test system. Copyright© 2004 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved ER -